AUTHORS
Jie Bai, PhD, Tian Li2, Ziyang Shen3, Maiko Sezaki, PhD4, Xuan Zhang5, Vincent Pham6, Alejandra Lorenzen7, Min Xiong8, Punam Malik, MD9, H. Leighton Grimes, PhD10, Jun Liu, MD, PhD11, Li Chai12, Dong Liu, PhD13, Shaojiang Deng, PhD14, Gang Huang, MD15
AFFILIATIONS
1 UT Health San Antonio, San Antonio, Texas, United States
2 UT Health San Antonio, San Antonio, Texas, United States
3 Brigham and Women's Hospital, Boston, Massachusetts, United States
4 UT Health San Antonio, San Antonio, Texas, United States
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 UT Health San Antonio, San Antonio, Texas, United States
7 UT Health San Antonio, San Antonio, Texas, United States
8 Kind Pharmaceuticals LLC, Redwood City, California, United States
9 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
10 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
11 Brigham and Women's Hospital, Boston, Massachusetts, United States
12 Brigham and Women's Hospital, Boston, Massachusetts, United States
13 Kind Pharmaceuticals LLC, Redwood City, California, United States
14 Kind Pharmaceuticals LLC, Redwood City, California, United States
15 UT Health San Antonio, San Antonio, Texas, United States
ABSTRACT
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, impaired terminal erythroid maturation, oxidative stress, and shortened red blood cell (RBC) lifespan, which collectively contribute to anemia and disease progression. Current therapies primarily target vaso-occlusive complications or increase fetal hemoglobin (HbF), as with hydroxyurea (HU), while therapeutic approaches that directly improve erythroid maturation and RBC quality remain limited. Given the critical role of hypoxia signaling in erythropoiesis and mitochondrial clearance during terminal erythroid maturation, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may represent a strategy to promote erythroid maturation and improve RBC quality in SCD. AND017 is a novel oral HIF-PHI that has advanced to Phase 2 clinical trials for anemia associated with chronic kidney disease (CKD). Here, we investigated the therapeutic potential and underlying mechanisms of AND017 in a preclinical model of SCD, with a focus on erythroid maturation, mitochondrial clearance, RBC lifespan, and hematologic outcomes.
AND017 was evaluated in the Townes SCD mouse model following oral administration at 30 mg/kg in meglumine vehicle three times weekly, initiated after the onset of hematologic abnormalities, and compared with erythropoietin (EPO) and the previously studied HIF-PHIs roxadustat and daprodustat. Hematologic parameters, RBC lifespan, erythroid differentiation, transcriptomic profiles, and metabolic changes were evaluated using flow cytometry, RNA sequencing, and functional assays. To further investigate the underlying mechanisms, mouse erythroleukemia (MEL) cells were used as an in vitro model of erythroid differentiation and treated with vehicle or AND017 for up to 4 days.
Among the HIF-PHIs tested, AND017 produced the most pronounced and sustained improvements in RBC count, hemoglobin, and hematocrit. AND017 reduced reticulocytosis, RBC sickling, lymphocytosis, and splenic extramedullary erythropoiesis, while extending RBC lifespan and improving overall survival. Mechanistically, AND017 enhanced terminal erythroid maturation and enucleation without substantially altering hematopoietic stem and progenitor cell frequencies or their core transcriptional programs in SCD mice. Transcriptomic analysis of erythroid progenitors revealed activation of hypoxia signaling and glycolytic pathways, with suppression of oxidative phosphorylation and induction of the HIF target gene BNIP3. The induction of BNIP3, a key regulator of mitophagy, was associated with enhanced mitochondrial clearance during erythroid maturation following AND017 treatment. AND017 reduced mitochondrial retention together with mitochondrial reactive oxygen species and lipid peroxidation, consistent with attenuated oxidative stress in erythroid cells from SCD mice. Mechanistic studies in MEL cells further demonstrated that AND017 promoted mitochondrial clearance and activated HIF-dependent hypoxia signaling and glycolytic programs.
These findings highlight the potential of AND017 to improve both RBC quantity and quality by targeting fundamental defects in erythroid maturation and mitochondrial clearance in SCD setting. The established clinical development of AND017 in CKD-associated anemia provides a translational foundation for its evaluation in SCD and potentially other erythroid disorders characterized by ineffective erythropoiesis or erythroid dysfunction. Taken together, these findings position AND017 as a promising oral therapeutic strategy that targets fundamental defects in erythroid maturation and RBC quality through mechanisms distinct from currently available SCD therapies, supporting further clinical evaluation of AND017 in SCD.
DISCLOSURES
Jie Bai, PhD: No relevant conflicts of interest to declare.